For a patient on two oral antidiabetic medications and an A1C of 10%, what is the appropriate next step?

For a patient on two oral antidiabetic medications and an A1C of 10%, what is the appropriate next step?

• A. Start basal insulin (levemir)
• B. Increase dose of oral meds
• C. Add GLP-1 receptor agonist
• D. Switch to metformin only

Answer: (D)

When A1C is 10% despite being on two oral antidiabetic meds, the goal is to intensify therapy rather than reduce it. A long-standing A1C in the double digits signals that oral agents alone aren’t enough to control both fasting and postprandial glucose, so starting an injectable option is typically indicated. Beginning basal insulin provides steady, background insulin that lowers fasting plasma glucose and tends to produce a meaningful drop in overall A1C. A common starting plan is about 10 units at night (or 0.1–0.2 units/kg), with careful titration by small increments every few days to reach a fasting target around 80–130 mg/dL, while monitoring for hypoglycemia and adjusting diet and activity as needed. An alternative injectable choice is a GLP-1 receptor agonist, which can improve A1C, often promotes weight loss, and has a lower risk of hypoglycemia when not combined with insulin. The choice depends on patient factors such as weight goals, hypoglycemia risk, injection tolerance, and cost. Simply increasing the dose of oral meds is unlikely to achieve target with an A1C this elevated, and switching to metformin alone would discard the current therapeutic gains from the other agents. The key concept is to escalate therapy to more effectively control glucose levels.

When A1C is 10% despite being on two oral antidiabetic meds, the goal is to intensify therapy rather than reduce it. A long-standing A1C in the double digits signals that oral agents alone aren’t enough to control both fasting and postprandial glucose, so starting an injectable option is typically indicated. Beginning basal insulin provides steady, background insulin that lowers fasting plasma glucose and tends to produce a meaningful drop in overall A1C. A common starting plan is about 10 units at night (or 0.1–0.2 units/kg), with careful titration by small increments every few days to reach a fasting target around 80–130 mg/dL, while monitoring for hypoglycemia and adjusting diet and activity as needed.

An alternative injectable choice is a GLP-1 receptor agonist, which can improve A1C, often promotes weight loss, and has a lower risk of hypoglycemia when not combined with insulin. The choice depends on patient factors such as weight goals, hypoglycemia risk, injection tolerance, and cost.

Simply increasing the dose of oral meds is unlikely to achieve target with an A1C this elevated, and switching to metformin alone would discard the current therapeutic gains from the other agents. The key concept is to escalate therapy to more effectively control glucose levels.